Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Merck Statement In Response To The FDA's June 12, 2009 Communication With Updated Information On Leukotriene Inhibitors, Including SINGULAIR(R)
Merck & Co., Inc. issued the following statement in response to today"s communication from the U.S. Food & Drug Administration (FDA) addressing updated information on leukotriene inhibitors, including SINGULAIR® (montelukast sodium).
generic viagra online
Mabthera(R) (Rituximab) Available On NHS For UK's Most Common Leukaemia
The National Institute for Health and Clinical Excellence (NICE) today issued its recommendation for the use of MabThera® (rituximab) in the UK"s most common form of leukaemia, chronic lymphocytic leukaemia (CLL).1,2,3 NICE"s final guidance recommends rituximab in combination with fludarabine and cyclophosphamide (FC) chemotherapy as an option for previously untreated patients with CLL.4 The addition of rituximab to FC chemotherapy has been proven to halt progression of the disease by 10.5 months longer than chemotherapy alone, and more than doubles the number of CLL patients achieving complete remission, compared to chemotherapy.5,6 More than 20,000 people in the UK are living with CLL and there are an estimated 3,700 new cases every year.7,8 Professor John Gribben, Consultant Haematologist and Medical Oncologist, Barts and The London NHS Trust, commented:
News of the day
Pfizer Discontinues Phase 3 Trial Of Sutent(R) In Metastatic Colorectal Cancer
Pfizer Inc announced the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus FOLFIRI alone for the first-line treatment of metastatic colorectal cancer (CRC). The independent Data Monitoring Committee (DMC) found that the addition of sunitinib to the chemotherapy regimen FOLFIRI would be unable to demonstrate a statistically significant improvement in the primary endpoint of progression-free survival (PFS) compared to FOLFIRI alone, in this study. No new safety issues were identified.
Endocrinology

Health Protection 2009 Conference - Programme Announced, UK

The Health Protection Agency (HPA) has announced an innovative and wide-ranging programme for the Health Protection 2009 conference, which is taking place at Warwick University from 14th to 16th September. The conference programme focuses on the three key areas of the HPA"s work - preventing and controlling infectious diseases, protecting against radiation, chemical and environmental hazards; and preparing for potential and emerging threats to health - and features expert contributions from a number of public and private sector organisations involved in public health work. Justin McCracken, Chief Executive of the HPA, said, "The annual health protection conference is a leading event for those involved in public health and I"m delighted to be announcing a programme that offers such a wide range of presentations on issues that are at the heart of our work. "With such a diverse programme and with contributions from experts in such a variety of fields, the conference will be a great opportunity for health professionals and scientists to broaden their knowledge of issues that are at the forefront of health protection." Highlights of the four track programme include symposia on: - Responding to health emergencies (with presentations from experts at the HPA, Civil Contingencies Secretariat and the Office for Security & Counter Terrorism); - Sexually Transmitted Infections (featuring lectures from experts at the HPA, Health Protection Scotland, the National Chlamydia Screening Programme, the Scottish Consortium and St. George"s, University of London); - Protecting the health of healthcare workers (organised with Health Protection Scotland) Attendees of the conference will also have the opportunity to be briefed on the latest swine flu developments, from experts at the HPA, whose guidance for the government, health professionals and the public has been instrumental in shaping the country"s response to the current pandemic. Other highlights include a session on assessing and valuing health risks, with speakers from the HPA and the London School of Hygiene and Tropical Medicine; and a session on translating science in to novel interventions, with input from Baxter Innovations. Professor Gordon Dougan, Head of Pathogen research and a member of the Board of Management - the Wellcome Trust Sanger Institute, Cambridge, will give the Turnberg Lecture on Monday 16th September. His lecture will be on "selective evolution in microbial genomes; implications for infection control". This conference will be attended by well over 1,200 specialists, in all fields of health protection. Those interested in attending should visit the conference website - http://www.healthprotectionconference.org.uk - for a full programme and to book a place. Email: hpaconference@hpa.org.uk Notes 1. The Health Protection 2009 conference will be held at Warwick University from 14th to 16th September. To book a place and for further information, visit http://www.healthprotectionconference.org.uk Health Protection Agency


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009